Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & B

Pfizer

Status: Withdrawn

Conditions: Hemophilia B; Hemophilia A

Study type: Observational

Funder types: Industry

Identifiers

NCT06634836

NCT06634836 (Registry Identifier)

C3731011

Details and patient eligibility

About

The purpose of this study is to learn about experiences of patients with hemophilia A and B after taking gene therapy. The experiences of patients will be studied through online interviews.

This study is seeking participants who are:

• part of the Pfizer's gene therapy clinical studies or
• in the long-term follow up for these clinical programs. Participants will have one study visit at the clinic and one online interview. The planned duration for each participant will be 1 to 2 months. This covers the time from entering the study to end of the online interview.

Sex: Male

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participation in the Pfizer's gene therapy clinical trials for Hemophilia A or B .
• Participants will be one year or more post-gene therapy
• Participants will be willing to provide written consent and will be willing to comply with the study requirements

Exclusion criteria

-No exclusion criteria

Trial design

0 participants in 1 patient group

Hemophilia A and Hemophilia B patients

Description:

Patients who are participating in the Pfizer's gene therapy clinical trials for Hemophilia A or Hemophilia B or are in the long-term follow up for these clinical programs